SYTE.bio SYTE.bio
ES
SYNTHETIC BIOLOGY

Transforming Life. End to End.

Non-Viral DNA & RNA Medicines

We combine Molecular Engineering, Non-Viral Delivery, and Intelligent Software in one Platform, Accelerating the Creation of Advanced Medicines for Animals and Humans

Discover the Future

Our Technology

Life runs on DNA and RNA

SYTE.bio engineers both to develop non-viral vaccines and gene therapies that address disease at its source. Our platforms deliver precise genetic instructions that turn a patient's own cells into therapeutic factories. The cells produce the required antigen or therapeutic molecule, training the immune system, targeting disease mechanisms, or enhancing natural biological functions.

The sequence is the medicine

New products can be developed by redesigning the code, not rebuilding the manufacturing process. This enables faster development, scalable production, repeat dosing, and applications across human and animal health.

SYTE.bio owns the full stack

  • Computational design for Antigens, Nucleic-Acid Constructs, Ribozymes, and Aptamers
  • Proprietary DNA and RNA platforms
  • Proprietary Chemical and Device-based Delivery

One integrated platform. Vaccines and gene therapies by design. No viral vectors.

Platforms Delivery Devices Bioinformatics
Why non-viral

Advantages of Non-Viral Gene Therapies and Vaccines

Six criteria where a non-viral, fully synthetic approach outperforms traditional viral delivery.

VIRAL VECTORS

{{ v.label }}
{{ row.con }}

DNA & RNA PLATFORMS

L-DNA
L-RNA
C-DNA
C-RNA
SMART-DNA
{{ row.pro }}
Advanced delivery

Every Medicine Needs the Right Way In.

We develop both chemical and physical delivery systems in-house, giving each therapy the route best suited to its target. When specialized hardware is required, it is developed through our spin-off, Healix Instruments.

Chemical methods

Proprietary Vehicles

Organic and inorganic nanoparticles plus FDA- and EMA-approved drug repurposing for DNA and RNA transfection: gelatin, PEI and chitosan-alginate formulations.
Physical methods

Medical Devices - Electroporator

Healix Instruments electroporator

Electroporation, pressure-mediated transfection, magnetoporation and sonoporation. No excipients required; a device is. Our spinoff Healix Instruments delivers high transfection rates at lower doses, with reduced cytotoxicity and unwanted immune response.
Manufacturing

DNA vs Viral Vector Manufacturing

Viral Vector Manufacturing
Viral vector manufacturing flow

A long multi-step process: manufacturing stability risk, ultra-high cost and biosafety risk.

Non-Viral DNA Manufacturing
Non-viral manufacturing flow

DNA manufacturing only — lower cost, reduced biosafety risk, and a process that scales.

Where we focus

Human Health

Vaccines

We pioneer adaptive vaccine design using DNA and RNA platforms to express single or multi-antigen profiles that can be combined with immune-enhancing adjuvants. DNA vaccines establish enduring immune memory, while RNA rapidly delivers antigens for emerging threats.

See all Human Vaccines →

Therapies

Our platforms empower precision medicine by tailoring expression timelines to disease demands: long-term solutions for chronic conditions like diabetes and osteoarthritis, mid-term therapies for pain management and oncology, and short-term interventions for acute issues such as dermatitis.

See all Human Therapies →

Animal Health

Vaccines

We engineer vaccines targeting multi-pathogen threats like parasites, viruses and other microorganisms with integrated immune boosters. DNA ensures robust, long-lasting livestock and companion animal protection, while RNA enables agile responses to zoonotic outbreaks.

See all Animal Vaccines →

Therapies

Species-specific therapies calibrated to animal health needs: long-term genetic expression for inherited disorders, mid-term modulation for degenerative conditions, and short-term interventions for transient gene-related conditions.

See all Animal Therapies →
Pipelines

Most advanced programs

Explore all pipelines →
Animal health
Animal · Oncology

Melanoma · Canine
Animal · Oncology

Sarcoma · Canine
Animal · Vaccines

Bovine Leukemia Virus Vaccine
Human health
Human · Oncology

Melanoma
Human · Infectious

Andes Virus
About us

SYTE.bio

As a Leading Synthetic Biology Company, our main goal is to combine Unique Human Talent with Cutting-Edge Technology to Develop Better, Safer, and More Effective Therapeutics, Enhancing Quality of Life and Longevity for Millions of Humans and Animals.

More About SYTE.bio
SYTE.bio DNA Vaccine vial

A company built on values,
lead to generate impact.

SYTE.bio is a leading Synthetic Biology company, clinical stage in Animal Health, specializing in DNA and RNA-based vaccines and gene therapies. Our advanced proprietary platforms are designed for safety, stability, and efficacy, offering non-viral solutions that redefine treatment possibilities for severe medical conditions.

By harnessing Cutting-Edge Synthetic Biology, we enhance therapeutic delivery, molecular stability, and immune response while minimizing risks associated with traditional approaches.

Mission

Our mission is to lead a global transformation in medicine by leveraging innovative synthetic biology platforms to deliver safe, effective, and non-viral DNA and RNA-based therapeutics and vaccines. We aim to address urgent medical challenges and provide solutions for diseases with unmet clinical needs, ensuring accessibility and affordability for patients worldwide.

Vision

We envision a future where advanced synthetic biology enables precise, personalized, and preventative medicine for all. SYTE.bio strives to be a world leader in the development and commercialization of next-generation nucleic acid-based therapies and vaccines, shaping the future of healthcare and empowering communities to live healthier, longer lives.
Values

What holds us together

Innovation

We embrace cutting-edge science and technology to pioneer breakthroughs in synthetic biology and nucleic acid therapeutics.

Safety & Integrity

We deliver safe, non-viral solutions while maintaining the highest ethical and scientific standards in all our endeavors.

Patient-Centric Focus

Everything we do revolves around improving the lives of patients, offering accessible, precise, and transformative therapies.

Collaboration

We foster strong partnerships with researchers, healthcare providers, and communities to drive collective progress.

Sustainability

We design scalable and cost-effective solutions that promote global accessibility and environmental sustainability.
Partnering

Ways to work with us

We build with partners across pharma, veterinary health, academia and capital markets.

Co-development

Bring an indication or antigen; we design, build and test the construct on the platform best matched to the required expression window.

Talk to us →

Platform licensing

Access L-DNA, C-DNA, SMART-DNA and our RNA platforms for defined fields of use, backed by our European patent estate.

Talk to us →

Investment

A clinical-stage portfolio spanning human and animal health, with animal oncology programs already in late-stage development.

Talk to us →
Leadership

Unique Human Talent

Martin Williams

CEO & Founder

Mariano Belaich

CSO & Co-Founder

Dalila Silvestre

Director of R&D

Carolina Alarco

Senior Biotech Executive

Juan Pablo Tevini

Legals

Augusto Tevini

Finances

Sebastián Ulla

Research Associate

Maria Ruscitti

Research Associate

First-In-Kind
Proprietary Technologies

SYTE.bio develops next-generation, non-viral DNA and RNA technologies for human and animal health. Our integrated platforms combine nucleic acid design, chemical and physical delivery systems, and advanced bioinformatics to create vaccines and gene therapies engineered for safety, stability, scalability, and repeat dosing.

By designing the entire technology stack, from molecule to delivery device, we build solutions ready to translate from research to real-world application. Our innovations are protected by granted patents.

{{ p.groupTitle }}
{{ p.tag }} {{ p.status }}

{{ p.name }}

Modules
{{ mo.name }}

{{ mo.note }}
{{ p.galleryLabel }}
{{ gi.label }}

Applications

{{ p.apps }}

Key features
{{ f }}

Proprietary computational pipelines

Epitope prediction · Construct design
Ribozyme & aptamer engineering

Allele selection → Epitope prediction → Immunogenicity & stability → Structural modelling → Ranking & selection
epitope_pipeline.py
from pipefunc import Pipeline, pipefunc


from syte.immuno import mhc_panel, netmhc




@pipefunc(output_name="alleles")


def select(species):


    return mhc_panel(species, coverage=0.95)




@pipefunc(output_name="epitopes")


def predict(seq, alleles):


    return netmhc(seq, alleles, k=(8, 11))




@pipefunc(output_name="ranked")


def rank(epitopes, structures):


    return score(epitopes, structures)




pipeline = Pipeline([select, predict, rank])


pipeline.visualize()

Antigen candidates are selected computationally before a single construct is built: species-specific MHC allele panels, 8–11-mer binding-register prediction, immunogenicity and stability scoring, then structural validation and ranking.

Allele panels per target species, tuned for population coverage.
Peptide–MHC screening across 8–11-mer binding registers.
Immunogenicity, stability and self-similarity filters.
Structural superposition against reference antibody–antigen complexes.
Peptide–MHC screening
Peptide–MHC screening

8–11-mer binding-register analysis.

Structural superposition
Structural superposition

Predicted vs. reference antibody–antigen complex.
construct_design.py
# construct assembly


from syte.constructs import Cassette, dnts, qc




cds = optimize_codons(antigen, host="canis_lupus")


cassette = Cassette(


    promoter="CAG", cds=cds, poly_a="bGH",


    nuclear_transport=dnts(copies=2),


)




# circular RNA: IRES, no chemical cap


crna = cassette.to_rna(ires="CVB3", capless=True)


crna.minimize_structure(window=120)




report = qc(cassette, crna)


report.check("sites", "gc", "repeats")


report.export("release.json")

The same codebase designs the molecules themselves. DNA and RNA construct pipelines assemble regulatory elements, insert nuclear-transport sequences, convert cassettes into cap-free circular RNA, and gate every batch on manufacturability.

Codon optimization per target species and tissue.
Cassette assembly: promoter, CDS, polyA and DNTS copies.
RNA variants with IRES-driven, cap-free translation initiation.
Manufacturability gate: restriction sites, GC windows, repeats.
+40%
Nuclear entry · DNTS
1 – n
Genes per construct
DNA · RNA
Shared design chain
JSON
Release record per batch
ribozyme_design.py
# ribozyme design for circularization


from syte.rz import scan, arms, fold, kinetics




sites = scan(linear_rna, motif="10-23")


cands = [arms(x, length=9) for x in sites]




for cz in cands:


    cz.dG = fold(cz.duplex).dG   # RNAfold


    cz.kobs = kinetics(cz, mg=10, temp=37)




best = rank(cands, by=("dG", "-kobs"))[:3]


assert_closed(best[0], rnase_r=True)

Circular RNA needs a catalyst. We scan the linear transcript for cleavage sites, design DNAzyme binding arms, compute folding free energy and observed kinetics, then confirm the closed product survives RNAse R.

Site scanning across the transcript for 10-23 DNAzyme motifs.
Binding-arm design with folding free-energy minimization.
Kinetic ranking under defined Mg²⁺ and temperature.
Circularization confirmed by RNAse R resistance.
Circularized product
Circularized product

DNAzyme-mediated circularization of the linear IVT transcript.

10-23
DNAzyme motif
RNAse R +
Exonuclease challenge
ΔG · kobs
Ranking criteria
aptamer_design.py
# aptamer design — in-silico SELEX


from syte.apta import library, fold3d, dock, label




lib = library(n=10**6, length=40)


pool = lib.filter(fold3d, motifs=["g-quad"])




hits = dock(pool, target="PTK7_ECD", n=20)


hits = hits.rank(by="dG_bind", cutoff=-9.5)




apta = label(hits[0], dye="FAM", site="5p")


apta.cap("SMART-DNA")   # capped ends

Aptamers give our DNA constructs their targeting and self-delivery. An in-silico library is folded, docked against the receptor ectodomain, ranked by binding free energy, then labelled and used to cap SMART-DNA ends.

In-silico library generation under GC and length constraints.
Three-dimensional folding filters for G-quadruplex and stem-loop motifs.
Replica docking against the target receptor ectodomain.
Validated in vitro.
Binding-site docking
Binding-site docking

Ligand density and epitope interface.

Aptamer binding, in vitro
Aptamer binding, in vitro

Membrane-localized FAM signal on target-positive cells.

Code shown is illustrative of the pipeline architecture, not production source. Figures are representative in silico and in vitro analyses.

DNA & RNA platform IP

Three families granted across the United States and Europe.

Ref
Number
Title
Priority
Status
1
EP4219723 (B1)
US20230235337
Circular RNA platforms, uses thereof, and manufacturing processes from engineered DNA
2022
Granted
2
EP4141119 (A3)
US20230128316
Hairpin-loop-ended self-complementary double-stranded covalently closed linear DNA vector, manufacturing system and process, and uses thereof
2022
EU granted US pending
3
18/799,681
System and process for in-vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA, the resulting molecules and their uses
2024
US granted

Granted families

EP 4 219 723 Granted · EPO

Circular RNA platforms, uses thereof, and their manufacturing processes from engineered DNA.
EP 4 141 119 EU granted

Hairpin loop ended self-complementary double-stranded covalently closed linear DNA vector, manufacturing system and process.
US 12,509,711 B1 Granted · USPTO

System and process for in-vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA.

Our Advanced
Developments

Programs across human and animal health, tracked from research to market launch.

{{ g.title }}

{{ g.count }}
{{ g.speciesLabel }}
Program
{{ ph.label }}
Status
{{ r.species }}
{{ r.name }}
{{ r.status }}
Healix Instruments · electroporator

Needle-free, outpatient by design

The applicator our most advanced canine oncology programme is dosed with: proprietary pulse protocols, higher transfection at lower nucleic-acid doses, no excipients.

Healix Instruments electroporator
Working prototype
Transparent housing
Working electroporator prototype with transparent housing

Pulse board, capacitor bank and applicator head assembled — the functional unit behind the industrial design.

Resin 3D-printed housing on the print platform
Prototyping in-house

Housings are iterated as resin 3D prints — form, grip and applicator geometry tested between design cycles before tooling.

Milestones and
Scientific Progress

Milestones, scientific work, and conference presence.
{{ n.number }} {{ n.office }}
{{ n.kind }} {{ n.meta }} {{ n.date }}

{{ n.title }}

{{ n.body }}

{{ n.linkLabel }}
Contact

Join us to transform the world!

Let’s deliver innovative solutions to those who need them most.

Send a message

Send →

Join us to transform the world!

Let’s deliver innovative solutions to those who need them most.

Contact